An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary Angioedema

Aleena Banerji; Timothy Craig; Karl Sitz; H. Henry Li; William R Lumry; Adil Adatia; William Yang; Josh S. Jacobs; Raffi Tachdjian; Weily Soong; Michael Manning; James H. Wedner; Sinisa Savic; Ania Manson; Anna Valerieva; Michele Gunsior; Ganesh Mugundu; Theodora Cohen; Kristine Bernard; Claire VanEenwyk; Kusumam Joseph; Jessica Best; Christopher Morabito; Marc A. Riedl

doi:10.1016/j.jaci.2026.02.034

Key Points

This study investigates the effectiveness and tolerance of navenibart in reducing attacks of hereditary angioedema.
Conducted as an open-label phase 1b/2 trial
Administered navenibart to participants every 3 or 6 months
Monitored frequency of hereditary angioedema attacks
Navenibart was well tolerated by participants
Significantly reduced the frequency of hereditary angioedema attacks
Support for administering navenibart every 3 or 6 months

Implication

An open-label phase 1b/2 trial demonstrates reduced hereditary angioedema attacks with navenibart treatment, indicating its effectiveness.

Abstract

Navenibart was well tolerated and substantially reduced hereditary angioedema attacks, providing support for every-3-month and every-6-month administration of navenibart to prevent hereditary angioedema attacks.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Banerji et al. (2026) studied this question.

synapsesocial.com/papers/69af944f70916d39fea4b51f https://doi.org/10.1016/j.jaci.2026.02.034

View Full Paper

Ask AI

Bookmark

Share

An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary Angioedema

Key Points

Implication

Abstract

Discussion

Cite This Study

An Open-Label Phase 1b/2 Trial of Navenibart, a Long-Acting Plasma Kallikrein Inhibitor for Hereditary Angioedema

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading